Glutamine addiction is a therapeutic target to block emergency myelopoiesis

This study identifies glutaminolysis as a critical metabolic dependency in emergency myelopoiesis driven by Myc, demonstrating that targeting this pathway pharmacologically or genetically can selectively suppress pathological myeloid overproduction and inhibit breast tumor progression without compromising normal hematopoiesis.

The Gist

The Big Picture: The Body's "Emergency Factory"

Imagine your body's immune system is a massive, well-organized factory. Under normal conditions, this factory (located in your bone marrow) produces just enough "security guards" (white blood cells, specifically neutrophils) to keep you safe. This is steady-state myelopoiesis.

But sometimes, the factory gets a massive, urgent order. Maybe you have a severe infection, or perhaps you have cancer. The body screams, "We need more guards, NOW!" This is called Emergency Myelopoiesis (EM). The factory goes into overdrive, cranking out guards at a breakneck speed.

The Problem: In diseases like breast cancer, this emergency factory goes into overdrive too much. It produces a flood of immature, aggressive guards that actually help the cancer grow and spread, rather than fighting it. Scientists have struggled to shut down this "emergency mode" without stopping the factory entirely (which would leave you defenseless against real infections).

The Discovery: The Factory's Secret Fuel

This paper, by Olson and colleagues, discovered exactly what fuel this "emergency factory" runs on, and how to cut off the supply.

1. The "Normal" Workers vs. The "Emergency" Workers

The researchers found that the factory has two different types of workers with different diets:

• The Veteran Managers (Stem Cells): These are the quiet, long-term workers who keep the factory running for years. They are very careful with their energy. They make their own fuel (glutamine) inside the factory so they don't have to rely on outside supplies. They are like a self-sustaining garden that doesn't need delivery trucks.
• The Emergency Workers (Progenitors): When the "Emergency Mode" is triggered, new workers are hired. These workers are hyperactive. They don't make their own fuel; they are addicted to a specific fuel truck delivering Glutamine.

2. The "Myc" Boss and the Engine

Why are these emergency workers so hungry? The paper found a "boss" protein called Myc.

• In normal times, Myc is quiet.
• In emergency times, Myc goes into overdrive. It tells the workers to build massive, high-performance engines (mitochondria) to burn fuel fast.
• Because these engines are running so hot, they need a constant stream of Glutamine to keep the fire burning. If you cut off the Glutamine, the engines stall, and the factory stops producing the flood of guards.

The Solution: Cutting the Fuel Line

The researchers tested a simple idea: What if we starve the emergency workers of Glutamine?

They used two methods to do this in mice:

1. Genetic Lock: They genetically removed the "engine" that processes Glutamine (an enzyme called Glutaminase) in the bone marrow.
2. Chemical Block: They gave the mice a drug (DON) that blocks the Glutamine fuel line.

The Results were amazing:

• The Emergency Stops: The factory stopped overproducing the "bad" guards. The flood of neutrophils dried up.
• The Cancer Starves: In mice with breast cancer, the tumors stopped growing as fast. Why? Because the cancer was relying on those overproduced guards to help it grow and hide from the immune system. Without the guards, the cancer was exposed and slowed down.
• Safety First: Crucially, the "Veteran Managers" (the stem cells) were fine. They didn't need the outside Glutamine fuel because they make their own. So, the factory didn't collapse; it just stopped the panic production.

The Analogy: The Pizza Delivery

Think of it like a pizza shop:

• Normal Days: The shop makes a few pizzas a day. The owner (Stem Cell) bakes them in a small oven using ingredients they grow in their own garden. They are self-sufficient.
• Emergency Days (Cancer): A huge order comes in. The owner hires a bunch of temp workers. These temps don't have a garden; they rely entirely on a specific delivery truck bringing Glutamine to the door. They also turn on a massive, roaring industrial oven (Myc-driven mitochondria) to cook fast.
• The Fix: If you block the delivery truck (Glutaminase inhibitor), the temp workers can't cook. The massive industrial oven sputters and dies. The flood of pizzas stops. But the owner, who grows their own ingredients, is totally fine and keeps the shop open for normal business.

Why This Matters

This is a game-changer for cancer treatment, specifically for breast cancer and other inflammatory diseases.

1. Precision Targeting: It offers a way to stop the "bad" immune cells that help cancer, without hurting the "good" immune cells that protect you.
2. Old Drugs, New Use: The drugs used to block this process (like DON) have been studied before for leukemia, but this paper suggests they could be repurposed for solid tumors like breast cancer by targeting the immune system's fuel supply, not just the cancer cells themselves.
3. A New Strategy: It suggests that to beat cancer, we might need to stop feeding the body's own emergency response system that the cancer has hijacked.

In short: The cancer is holding the body's immune factory hostage, forcing it to work overtime using a specific fuel. This paper found the fuel line and showed that cutting it stops the cancer's helpers without shutting down the whole factory.

Technical Summary

1. Problem Statement

Emergency myelopoiesis (EM) is a physiological response where the hematopoietic system rapidly expands myeloid cell production (specifically neutrophils) in response to stress, infection, or tissue damage. While essential for regeneration, chronic or maladaptive EM drives the progression of solid cancers (e.g., breast cancer) and inflammatory diseases by supplying tumor-promoting myeloid cells.

• The Gap: Current therapeutic strategies lack the ability to selectively suppress this pathological EM without compromising steady-state hematopoiesis or innate immune function.
• The Knowledge Gap: The specific metabolic programs that distinguish regenerative EM from steady-state myelopoiesis, and how hematopoietic stem and progenitor cells (HSPCs) adapt metabolically to fuel this rapid expansion, were poorly understood.

2. Methodology

The authors employed a multi-modal approach combining functional assays, single-cell genomics, and metabolic tracing in murine models:

• Single-Cell Transcriptomics (scRNA-seq): Used to map metabolic transcriptional programs across the hematopoietic hierarchy (HSCs, MPPs, GMPs) in steady-state versus regenerative conditions (induced by 5-Fluorouracil/5FU).
• Computational Flux Estimation: Applied a graph neural network model (scFEA) to estimate cell-wise metabolic fluxes from transcriptomic data.
• Genetic Manipulation: Utilized Cre-LoxP systems to create conditional knockout mice:
  • Scl-CreER: Hematopoietic-specific deletion of Myc (haploinsufficiency) and Glutaminase (Gls).
  • Mrp8-Cre: Neutrophil-specific deletion of Gls (to distinguish HSPC vs. mature cell requirements).
• Metabolic Inhibition & Tracing:
  • In vitro: Cultured LSK and GMP cells with inhibitors targeting Glutaminase (BPTES), Fatty Acid Oxidation (Etomoxir), and Pyruvate uptake (UK5099).
  • In vivo: Treated mice with 5FU, G-CSF, or breast cancer models (MMTV-PyMT/Py230) combined with Glutaminase inhibitors (DON) or Glutamine Synthetase inhibitors (MSO).
  • Isotope Tracing: Used $^{13}$C$_5$-glutamine to trace anaplerotic flux into the TCA cycle.
• Metabolic Assays: Seahorse extracellular flux analysis (OCR) for OXPHOS, Tomm20 immunofluorescence for mitochondrial content, and stable isotope tracing.

3. Key Contributions & Results

A. Metabolic Divergence Between HSCs and Progenitors

• HSC Survival Mechanism: Quiescent HSCs rely on de novo glutamine biosynthesis via Glutamine Synthetase (Glul) to maintain protein translation and proteostasis, rendering them independent of exogenous glutamine. Inhibiting Glul (with MSO) causes HSC death, but this is distinct from catabolic dependence.
• Progenitor Activation: Upon differentiation into myeloid progenitors (MPP3, GMP), cells switch from biosynthesis to catabolism, becoming dependent on exogenous glutamine.

B. The Role of Myc in Emergency Myelopoiesis

• Myc Hyperactivation: EM is driven by a massive upregulation of Myc transcriptional programs across the HSPC hierarchy.
• Mitochondrial Biogenesis: Myc drives mitochondrial biogenesis and a shift toward high oxidative phosphorylation (OXPHOS).
• Functional Consequence: Myc haploinsufficiency (Myc+/Δ) prevents the expansion of GMP clusters and the overproduction of immature neutrophils during 5FU-induced regeneration, confirming Myc is essential for EM.

C. Glutamine Addiction as a Therapeutic Vulnerability

• Metabolic Dependency: The hyperactivated TCA cycle in EM-driven progenitors is fueled specifically by glutaminolysis (glutamine $\to$ glutamate $\to$ $\alpha$-ketoglutarate).
  • Inhibition of glutaminase (BPTES) severely impaired LSK and GMP expansion in vitro.
  • Inhibition of FA oxidation or pyruvate uptake had no effect.
• Genetic Validation: Hematopoietic-specific deletion of Glutaminase (GlsΔ/Δ) in mice:
  • Had no impact on steady-state myelopoiesis.
  • Blunted EM: Delayed neutrophil recovery after 5FU and prevented the characteristic overproduction of neutrophils.
  • Rescue: The defect was rescued by supplementation with dimethyl-$\alpha$-ketoglutarate (dmKG), confirming the defect was due to TCA cycle fuel deprivation.
• Specificity: The requirement for glutaminase is restricted to HSPCs; deleting Gls in mature neutrophils (Mrp8-Cre) did not affect regeneration.

D. Therapeutic Efficacy in Cancer Models

• Breast Cancer Model (MMTV-PyMT/Py230):
  • Tumor growth induces EM via G-CSF, leading to Myc-driven glutamine addiction in HSPCs.
  • Genetic Targeting: GlsΔ/Δ mice showed reduced tumor growth, decreased bone marrow neutrophil reservoirs, and reduced intratumoral neutrophils (specifically the pro-tumorigenic T3 subset).
  • Pharmacologic Targeting: Treatment with DON (6-Diazo-5-oxo-L-norleucine), a broad-spectrum glutamine metabolism inhibitor, mimicked the genetic phenotype. It reduced tumor volume, depleted circulating neutrophils, and altered the tumor microenvironment (increasing CD4+ T cells) without affecting steady-state immunity when administered transiently.
  • Rebound Effect: The study noted a "myeloid rebound" after drug cessation, suggesting sustained treatment is necessary for clinical efficacy.

4. Significance

• Mechanistic Insight: The study defines a central regulatory axis where Myc hyperactivation drives mitochondrial biogenesis, creating a specific "glutamine addiction" in myeloid progenitors during stress. This distinguishes pathological EM from steady-state hematopoiesis.
• Therapeutic Strategy: It proposes that targeting glutaminase in HSPCs (rather than tumor cells) is a viable strategy to normalize maladaptive myelopoiesis. This approach starves tumors of pro-angiogenic and immunosuppressive neutrophils.
• Clinical Implications:
  • Explains why previous glutaminase inhibitors failed in breast cancer trials (they targeted tumor-intrinsic metabolism rather than the host's EM-driven myeloid supply).
  • Suggests repurposing anti-leukemic glutaminase inhibitors for solid tumors, particularly those with high neutrophil infiltration or high neutrophil-to-lymphocyte ratios (NLR).
  • Highlights the need for sustained dosing to prevent myeloid rebound.

Conclusion

Olson et al. demonstrate that emergency myelopoiesis relies on a Myc-driven metabolic switch to glutamine addiction. By targeting glutaminase in hematopoietic stem and progenitor cells, it is possible to selectively block the production of tumor-promoting neutrophils, thereby slowing breast cancer progression without compromising baseline immune function. This identifies a novel immunotherapeutic avenue for solid cancers driven by chronic inflammation.